Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

BACKGROUND: Sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new class of oral antihyperglycemic agents (AHAs) for the treatment of patients with type 2 diabetes. Type 2 diabetes is a life-long disease requiring chronic treatment and management. Therefore, robust a...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams-Herman, Debora, Round, Elizabeth, Swern, Arlene S, Musser, Bret, Davies, Michael J, Stein, Peter P, Kaufman, Keith D, Amatruda, John M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605739/
https://www.ncbi.nlm.nih.gov/pubmed/18954434
http://dx.doi.org/10.1186/1472-6823-8-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605739/
https://www.ncbi.nlm.nih.gov/pubmed/18954434
http://dx.doi.org/10.1186/1472-6823-8-14

Ejemplares similares